2015, Number S2
<< Back Next >>
Rev Med Inst Mex Seguro Soc 2015; 53 (S2)
Genes associated to cancer
Peralta-Rodríguez R,Valdivia A, Mendoza M,Rodríguez J, Marrero D, Paniagua L, Romero P, Taniguchi K, Salcedo M
Language: Spanish
References: 35
Page: 178-187
PDF size: 460.92 Kb.
ABSTRACT
In 2010, in a cancer genes census, 291 genes were enumerated. These
represent near to the 1 % of the total genes, for which there is enough
biological evidence that they belong to a new genes classification, known
as the cancer genes. These have been defined as the causal genes for
sporadic or familiar cancer, when they mutate. The mutation types for
these genes includes amplifications, point mutations, deletions, genomic
rearranges, amongst others, which lead to a protein over-expression,
muting, production of chimeric proteins or a
de novo expression. In conjunction
these genomic alterations or those of the genetic expression,
when they affect specific genes which contribute to the development of
cancer, are denominated as cancer genes. It is possible that the list of
these alterations will grow longer due to new strategies being developed,
for example, the genomic analysis.
REFERENCES
Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001;291 (5507):1304-1351.
International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004;431(7011):931-945.
Santarius T, Shipley J, Brewer D, Stratton MR, Cooper CS. A census of amplified and overexpressed human cancer genes. Nature 2010(1);10:59-64.
Bishop JM. Oncogenes. Sci Am. 1982;246(3):80-92.
Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004;4(9):665-676.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2/ neu oncogene. Science 1987;235(4785):177-82.
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first line treatment of HER2-overexpress9ing metastatic breast cancer. J Clin Oncol 2002;20(3):719- 726.
Esteller M, Guo M, Moreno V, Peinado MA, Capella G, Gaim O, et al. Hypermethylation associated inactivation of the Cellular Retinol-Binding Protein 1 Gene in Human Cancer. Cancer Res 2002;62:5902-5905.
Peralta R, Baudis M, Vazquez G, Juárez S, Ortiz R, Decanini H, et al. Increased expression of cellular retinol- binding protein 1 in laryngeal squamous-cell carcinoma. J Cancer Res Clin Oncol 2010;136(6):931-8.
Bignell GR, Santarius T, Pole JC, Butler AP, Perry J, Pleasance E, et al. Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution. Genome Res 2007;17(9):1296-1303.
Fix A, Lucchesi C, Ribeiro A, Lequin D, Pierron G, Schleiermacher G, et al. Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes. Genes Chromosom Cancer 2008;47(10):819-34.
Kaneko S, Ohira M, Nakamura Y, Isogai E, Nakagawara A, Kaneko M. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neroblastoma. J Cancer Res Clin Oncol 2007;133(3):185-92.
Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 2003;78(3):323-35.
Kallioniemi OP, Kallioniemi A, Sudar D, Rutovitz D, Gray JW, Waldman F, et al. Comparative genomic hybridization: a rapid new method for detecting and mapping DNA amplification in tumors. Semin Cancer Biol 1993;4(1):41-6.
Albertson DG, Pinkel D. Genomic microarrays in human genetic diseases and cancer. Hum Mol Genet 2003;12 Suppl 2:145-52.
Alloza E, Al-Shahrour F, Cigudosa JC, Dopazo J. A large scale survey reveals that chromosomal copynumber alterations significantly affect gene modules involved in cancer initiation and progression. BMC Med Genomics 2011;4(1):37.
Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54(3):794-9.
McIntyre A, Summersgill B, Grygalewicz B, Gillis AJ, Stoop J, van Gurp RJ, et al. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res 2005;65(18):8085-9.
Hayward NK. Genetics of melanoma predisposition. Oncogene 2003;22(20):3053-62.
González B, Salcedo M, Medrano ME, Mantilla A, Quiñónez G, Benítez-Bibriesca L, et al. RET oncogene mutations in medullary thyroid carcinoma in Mexican families. Arch Med Res 2003;34(1):41-9.
Agoff SN, Hou J, Linzer DI, Wu B. Regulation of the human hsp70 promoter by p53. Science 1993;259(5091):84-7.
Kim S, Chung DH. Pediatric solid malignancies: neuroblastoma and Wilms’ tumor. Surg Clin North Am 2006;86(2):469-87.
Vázquez-Ortiz G, Piña-Sánchez P, Salcedo M. Great potential of small RNAs: RNA interference and microRNA. Rev Invest Clin 2006;58(4):335-49.
Kao J, Pollack R. RNA interference-based funtional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Genes Chromosom Cancer. 2006;45(8):761-9.
Comoglio PM, Giardano S, Trusolino L. Drug development of MET inhibitors, targeting oncogene addiction and expedience. Nature Rev Drug Discov. 2008;7(6):504-16.
Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian M. The biology of chronic myeliod leukemia. N Engl J Med. 1999; 341(3):164-72.
Mehelen P, Fearon R. Role of dependence receptor DCC in colorrectal cancer pathogenesis. J Clin Oncol. 2004;22(16):3420:8.
Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol 2004;22(5):854-63.
Huff V. Wilms’ tumours: about tumour suppresor genes, an oncogene and chamaleon gene. Nat Rev Cancer. 2011;11(2):111-21.
Nikolsky Y, Sviridov E, Yao J, Dosymbekov D, Ustyansky V, Kaznacheev V, et al. Genome-wide funtional synergy between amplified and mutated genes in human breast cancer. Cancer Res 2008;68(22):9532-40.
Coate L, Cuffe S, Horgan A, Hung RJ, Christiani D, Liu G. Germline genetic variation, cancer outcome, and pharmacogenetics. J Clin Oncol 2010;28(26):4029-37.
Erickson RP. Somatic gene mutation and human disease other than cancer: an update. Mutat Res 2010;705(2):96-106.
Boehm T. Positional cloning and gene identification. Methods 1998;14(2):152-158.
Krontiris TG, Cooper GM. Transforming activity of human tumor DNAs. Proc Natl Acad Sci USA 1981;78(2):1181-4.
Finn RD, Mistry J, Tate J, Coggill P, Heger A, Pollington JE, et al. The Pfam protein families database. Nucleic Acids Res. 2010;38(Database issue):211-222.
Full text